{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:55:52Z","timestamp":1792122952198,"version":"4.4.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Janssen Global Services, LLC, a Johnson & Johnson company"},{"name":"Universit\u00e4tsklinikum M\u00fcnster"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>We examined real-world outcomes of patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with apalutamide plus androgen deprivation therapy (ADT). The current study, reflecting real-life practice, included specific subpopulations not evaluated in the pivotal phase III TITAN study: patients diagnosed with novel imaging, patients with M1a disease only, and patients treated with concomitant radiotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>ArtemisR is the first European multi-country observational study to retrospectively collect data from medical records of patients with mHSPC treated with apalutamide plus ADT in routine clinical practice. Response rates of patients with 50% and 90% decrease in PSA level (PSA50 and PSA90) compared with baseline and undetectable PSA (uPSA,\u2009&lt;\u20090.2 ng\/mL) were reported. Time to PSA response, time to metastatic castration-resistant prostate cancer (mCRPC), proportion of apalutamide discontinuation, and survival at 12 months were also examined using the Kaplan\u2013Meier method.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The analysis included 242 patients from Germany, France, Spain, and Austria; median age was 71 years. Median follow-up was 25.5 months from treatment initiation. Within 12 months of apalutamide initiation, 96% of patients achieved PSA50, 82% achieved PSA90, and 61% achieved uPSA. The median times to PSA50, PSA90, and uPSA were 1.08 months (95% confidence interval [CI]: 0.99\u20131.28), 1.94 months (95% CI: 1.54\u20132.27), and 3.48 months (95% CI: 2.92\u20135.68), respectively. At 12 months after treatment initiation, 94% of patients were alive, 91% had not progressed to mCRPC, and 81% remained on apalutamide plus ADT. Patients diagnosed with novel imaging, patients with M1a disease only, and patients treated with concomitant radiotherapy also showed deep and fast PSA responses (PSA90 and uPSA) with apalutamide plus ADT. Apalutamide-related adverse events (AEs) were reported in 90 patients (37%), and six patients (2.5%) discontinued apalutamide due to AEs. No new safety signals were detected.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The ArtemisR European multi-centre study examined the efficacy and safety of apalutamide plus ADT for patients with mHSPC, further validating the deep and fast PSA response associated with this treatment regimen. These real-world outcomes were additionally observed in a more diverse patient population than that included in the pivotal TITAN study.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12885-025-14294-7","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T07:12:48Z","timestamp":1751353968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Martin","family":"Boegemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostefa","family":"Bennamoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis Marie","family":"Dourthe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Antonio","family":"Encarnacion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Hegele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hellmis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Latorzeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Leicht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e1n","family":"O\u00f1ate-Celdr\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rosino-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystelle","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Lencart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Lukac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio A.","family":"Schioppa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzy","family":"Van Sanden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gero","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"14294_CR1","doi-asserted-by":"publisher","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","DOI":"10.3322\/caac.21834"},{"key":"14294_CR2","unstructured":"US National Cancer Institute. Cancer Stat Facts: Prostate Cancer. 2024. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html. Accessed August 2024."},{"key":"14294_CR3","doi-asserted-by":"publisher","unstructured":"Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. ESMO Guidelines Committee. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(9):1119\u201334. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.011.","DOI":"10.1016\/j.annonc.2020.06.011"},{"issue":"6","key":"14294_CR4","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","volume":"34","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Gillessen S. Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents. Ann Oncol. 2023;34(6):557\u201363. https:\/\/doi.org\/10.1016\/j.annonc.2023.02.015.","journal-title":"Ann Oncol"},{"key":"14294_CR5","doi-asserted-by":"publisher","unstructured":"Cornford P, van den Bergh RCN,\u00a0Briers E, Van Den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2024;86(2):148\u201363. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027.","DOI":"10.1016\/j.eururo.2024.03.027"},{"issue":"4","key":"14294_CR6","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1702900.","journal-title":"N Engl J Med"},{"issue":"10336","key":"14294_CR7","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fl\u00e9chon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet. 2022;399(10336):1695\u2013707. https:\/\/doi.org\/10.1016\/S0140-6736(22)00367-1.","journal-title":"Lancet"},{"issue":"32","key":"14294_CR8","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeirerlein J, Villers A, Azad A, et al. ARCHES: A randomized, phase iii study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974\u201386. https:\/\/doi.org\/10.1200\/JCO.19.00799.","journal-title":"J Clin Oncol"},{"issue":"15","key":"14294_CR9","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1200\/JCO.22.00193","volume":"40","author":"AJ Armstrong","year":"2022","unstructured":"Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2022;40(15):1616\u201322. https:\/\/doi.org\/10.1200\/JCO.22.00193.","journal-title":"J Clin Oncol"},{"issue":"12","key":"14294_CR10","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386(12):1132\u201342. https:\/\/doi.org\/10.1056\/NEJMoa2119115.","journal-title":"N Engl J Med"},{"key":"14294_CR11","unstructured":"ERLEADA Summary of Product Characteristics, 2023. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/erleada-epar-product-information_en.pdf. Accessed August 2024."},{"issue":"9","key":"14294_CR12","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s00432-024-05928-7","volume":"150","author":"A Hegele","year":"2024","unstructured":"Hegele A, H\u00e4u\u00dfermann R, Schultheis S, Skrobek L, Vink M, Hollwegs S, et al. Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study. J Cancer Res Clin Oncol. 2024;150(9):414. https:\/\/doi.org\/10.1007\/s00432-024-05928-7.","journal-title":"J Cancer Res Clin Oncol"},{"key":"14294_CR13","doi-asserted-by":"publisher","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med.\u00a02019;381(1):13\u201324.\u00a0https:\/\/doi.org\/10.1056\/NEJMoa1903307.","DOI":"10.1056\/NEJMoa1903307"},{"key":"14294_CR14","doi-asserted-by":"publisher","unstructured":"Chi KN, Chowdhury S, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study.\u00a0J Clin Oncol. 2021;39(20):2294\u2013303. https:\/\/doi.org\/10.1200\/JCO.20.03488.","DOI":"10.1200\/JCO.20.03488"},{"key":"14294_CR15","doi-asserted-by":"publisher","unstructured":"Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes AJ, Chung BH, et al. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.\u00a0Lancet Oncol. 2019;20(11):1518\u201330. https:\/\/doi.org\/10.1016\/S1470-2045(19)30620-5.","DOI":"10.1016\/S1470-2045(19)30620-5"},{"key":"14294_CR16","doi-asserted-by":"publisher","unstructured":"Chowdhury S, Bjartell A, Agarwal N, Chung BH, Given RW, Pereira de Santana Gomes AJ, et al. Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer. Ann Oncol. 2023;34(5):477\u201385. https:\/\/doi.org\/10.1016\/j.annonc.2023.02.009.","DOI":"10.1016\/j.annonc.2023.02.009"},{"key":"14294_CR17","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/bju.16449","volume":"6","author":"AS Merseburger","year":"2024","unstructured":"Merseburger AS, Agarwal N, Bjartell A, Uemura H, Soto AJ, Bhaumik A, et al. Targeted investigational treatment analysis of novel anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy. BJU Int. 2024;6:982\u201391. https:\/\/doi.org\/10.1111\/bju.16449.","journal-title":"BJU Int"},{"issue":"1","key":"14294_CR18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.prnil.2023.10.003","volume":"12","author":"A L\u00f3pez-Abad","year":"2024","unstructured":"L\u00f3pez-Abad A, Ram\u00edrez Backhaus M, Server G\u00f3mez G, Avellaneda EC, Alarc\u00f3n CM, Cubillana PL, et al. Real-world prostate-specific antigen reduction and survival outcomes of metastatic hormone-sensitive prostate cancer patients treated with apalutamide: An observational, retrospective, and multicentre study. Prostate Int. 2024;12(1):20\u20136. https:\/\/doi.org\/10.1016\/j.prnil.2023.10.003.","journal-title":"Prostate Int"},{"issue":"24","key":"14294_CR19","doi-asserted-by":"publisher","first-page":"21969","DOI":"10.1002\/cam4.6769","volume":"12","author":"JC S\u00e1nchez","year":"2023","unstructured":"S\u00e1nchez JC, Picola N, Rodriguez-Vida A, Cota M, Caste\u00f1eda DM, M\u00e1rquez MP, et al. Apalutamide for prostate cancer: Multicentre and multidisciplinary real-world study of 227 patients. Cancer Med. 2023;12(24):21969\u201377. https:\/\/doi.org\/10.1002\/cam4.6769.","journal-title":"Cancer Med"},{"issue":"14","key":"14294_CR20","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/pros.24599","volume":"83","author":"M Wenzel","year":"2023","unstructured":"Wenzel M, Garcia CC, Hoeh B, Jorias C, Humke C, Koll F, et al. Real-world evidence of outcomes of oligometastatic hormone-sensitive prostate cancer patients treated with metastasis-directed therapy. Prostate. 2023;83(14):1365\u201372. https:\/\/doi.org\/10.1002\/pros.24599.","journal-title":"Prostate"},{"issue":"6","key":"14294_CR21","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.3390\/cancers14061361","volume":"14","author":"AM Kase","year":"2022","unstructured":"Kase AM, Tan W, Copland JA 3rd, Cai H, Parent EE, Madan RA. The continuum of metastatic prostate cancer: Interpreting PSMA PET findings in recurrent prostate cancer. Cancers (Basel). 2022;14(6):1361. https:\/\/doi.org\/10.3390\/cancers14061361.","journal-title":"Cancers (Basel)"},{"issue":"13","key":"14294_CR22","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.3390\/diagnostics13132283","volume":"13","author":"M Zhu","year":"2023","unstructured":"Zhu M, Liang Z, Feng T, Mai Z, Zhou H, Chen Y, Yan W, et al. Up-to-date imaging and diagnostic techniques for prostate cancer: A literature review. Diagnostics (Basel). 2023;13(13):2283. https:\/\/doi.org\/10.3390\/diagnostics13132283.","journal-title":"Diagnostics (Basel)"},{"key":"14294_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.567616","volume":"10","author":"Y Wang","year":"2020","unstructured":"Wang Y, Gui H, Wang J, Tian J, Wang H, Liang C, et al. Comparative efficacy of combined radiotherapy, systemic therapy, and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: A network meta-analysis and systematic review. Front Oncol. 2020;10: 567616. https:\/\/doi.org\/10.3389\/fonc.2020.567616.","journal-title":"Front Oncol"},{"key":"14294_CR24","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: Long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36:1080\u20137. https:\/\/doi.org\/10.1200\/JCO.2017.75.3657.","journal-title":"J Clin Oncol"},{"issue":"10162","key":"14294_CR25","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(18)32486-3.","journal-title":"Lancet"},{"issue":"2","key":"14294_CR26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.eururo.2023.10.012","volume":"85","author":"M Miszczyk","year":"2024","unstructured":"Miszczyk M, Rajwa P, Yanagisawa T, Nowicka Z, Shim SR, Laukhtina E, et al. The efficacy and safety of metastasis-directed therapy in patients with prostate cancer: A systematic review and meta-analysis of prospective studies. Eur Urol. 2024;85(2):125\u201338. https:\/\/doi.org\/10.1016\/j.eururo.2023.10.012.","journal-title":"Eur Urol"},{"issue":"3","key":"14294_CR27","doi-asserted-by":"publisher","first-page":"556","DOI":"10.7150\/jca.29481","volume":"10","author":"Y Guo","year":"2019","unstructured":"Guo Y, Mao S, Zhang A, Wang R, Zhang Z, Zhang J, et al. Prognostic significance of young age and non-bone metastasis at diagnosis in patients with metastatic prostate cancer: A SEER population-based data analysis. J Cancer. 2019;10(3):556\u201367. https:\/\/doi.org\/10.7150\/jca.29481.","journal-title":"J Cancer"},{"issue":"6","key":"14294_CR28","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.urology.2013.01.061","volume":"81","author":"PF Schellhammer","year":"2013","unstructured":"Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology. 2013;81(6):1297\u2013302. https:\/\/doi.org\/10.1016\/j.urology.2013.01.061.","journal-title":"Urology"},{"key":"14294_CR29","doi-asserted-by":"publisher","unstructured":"Das P, Sharma A, Vengalil S, Khan Y, Lim JH, Elmasry A, et al. Does use of apalutamide enhance outcomes in combination with radiotherapy in metastatic hormone-sensitive prostate cancer? A real-world experience from the UK. J Clin Oncol. 2024;42(4_suppl):73\u201373. https:\/\/doi.org\/10.1200\/JCO.2024.42.4_suppl.73.","DOI":"10.1200\/JCO.2024.42.4_suppl.73"},{"key":"14294_CR30","doi-asserted-by":"publisher","unstructured":"Francolini G, Porreca A, Facchini G, Santini D, Bruni A, Simoni N, et al. Apalutamide and stereotactic body radiation therapy for low-burden, metastatic, hormone-sensitive prostate cancer: A randomized trial (PERSIAN). J Clin Oncol. 2024;42(4_suppl):TPS235. https:\/\/doi.org\/10.1200\/JCO.2024.42.4_suppl.TPS235.","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS235"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14294-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14294-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14294-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T07:12:51Z","timestamp":1751353971000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14294-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14294"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14294-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"19 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by Independent Ethics Committees (IECs)\/Institutional Review Boards (IRBs) at each participating institution, including Vienna General Hospital (Allgemeines Krankenhaus Wien) IRB\/IEC; Ethics Committee of the Medical Association of Westphalia-Lippe and the Medical Faculty of the Westphalian Wilhelms University of M\u00fcnster (Ethik-Kommission der \u00c4rztekammer Westfalen-Lippe und der Medizinischen Fakult\u00e4t der Westf\u00e4lischen Wilhelms-Universit\u00e4t M\u00fcnster); Ethics Committee at the Hesse State Medical Association (Ethikkommission bei der Landes\u00e4rztekammer Hessen); Hospital of the Brothers of Mercy Vienna (Krankenhaus Barmherzige Br\u00fcder Wien); Clinical Research Ethic Committee \u200b\u200bLe\u00f3n Health Area (Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica [CEIC] Area de Salud de Le\u00f3n); Clinical Research Ethic Committee of the Jos\u00e9 Mar\u00eda Morales Meseguer General University Hospital (CEIC del Hospital General Universitario Jos\u00e9 Mar\u00eda Morales Meseguer); Clinical Research Ethic Committee of the Virgen de la Arrixaca Hospital (CEIC del Hospital Virgen de la Arrixaca); and Ethics and Scientific Committee for Research, Studies and Evaluations in the Field of Health (Comite ethique et scientifique pour les recherches, les etudes et les evaluations dans le domaine de la sante [CESREES]). The need for informed consent was waived by Ethics Committee of the Medical Association of Westphalia-Lippe and the Medical Faculty of the Westphalian Wilhelms University of M\u00fcnster (Ethik-Kommission der \u00c4rztekammer Westfalen-Lippe und der Medizinischen Fakult\u00e4t der Westf\u00e4lischen Wilhelms-Universit\u00e4t M\u00fcnster) and many other IECs\/IRBs at each participating institution whose names are mentioned above. The study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice guidelines, and applicable regulatory requirements. An informed consent form waiver or opt-out letter process, as applicable, has been followed based on country- and site-specific requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M. Boegemann: Employment: Janssen; Honoraria: Advanced Accelerator Applications, Amgen, Astellas Pharma, AstraZeneca, Bayer\/Vital, Bristol Myers Squibb, Eisai, EUSA Pharma, Ipsen, Janssen-Cilag, Merck, MSD, Novartis, Pfizer, Roche, Sanofi\/Aventis; Consulting or Advisory Role: Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Ipsen, Janssen-Cilag, Merck, MSD, Novartis, Roche, Sanofi; Research Funding: Ipsen (Inst); Janssen-Cilag; Travel, Accommodation, Expenses: Amgen, Bayer, BMS GmbH & Co. KG, Janssen-Cilag. M. Bennamoun: Financial Interests, Invited Speaker: Janssen, AstraZeneca, Ipsen, Astellas. L.M. Dourthe: Honoraria: Janssen, Ipsen, Bayer, Pfizer. J.A. Encarnacion: Nothing to declare. A. Hegele: Advisor\/Honoraria\/Scientific lecture: Astra Zeneca, APOGEPHA, Pfizer, BMS, Ipsen, Janssen, Merck, MSD, Dr. Pfleger. E. Hellmis: Advisor\/Honoraria: Accord Healthcare, APOGEPHA, Astellas, AstraZeneca, Bayer Vital, BMS, Eisai, Hexal, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer, Recordati, Roche, Takeda. I. Latorzeff: Advisor\/Honoraria: Astellas, Bayer, BioProtect, Boston Scientific, Janssen, Ipsen. W. Leicht: Nothing to declare. J. O\u00f1ate-Celdr\u00e1n: Astellas, Bayer, Ipsen, GSK, Janssen, Recordati. A. Rosino-S\u00e1nchez: Advisor\/Honoraria: AstraZeneca \u2013 MSD, Astellas, Bayer, GP Pharm, Ipsen, Janssen, Recordati. K. Hanna: Full-time Employee: Janssen Pharmaceutica LLC; Shareholder: Johnson & Johnson. J. Lencart: Full-time Employee: Janssen Pharmaceutica LLC; Shareholder: Johnson & Johnson. M. Lukac: Employee: Parexel International S.R.O. On Behalf of Janssen Pharmaceutica LLC, a Johnson & Johnson Company. C.A. Schioppa: Full-time Employee: Janssen Pharmaceutica LLC; Shareholder: Johnson & Johnson. S. Van Sanden: Full-time Employee: Janssen Pharmaceutica LLC; Shareholder: Johnson & Johnson. G. Kramer: Honoraria or Consultation fee: Accord Healthcare, Astella, AstraZeneca, Bayer, Ferring, Ipsen, Janssen, MSD, Novartis, Pfizer, Takeda.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1119"}}